Last August, Flibanserin -- or "Addyi" -- became the first FDA-approved drug aimed at treating sexual dysfunction in women. Sprout, the company that developed the so-called “female Viagra” was understandably excited, and even more so the next day when they were bought by pharmaceutical giant Valeant, for one billion dollars. But after a rocky year, Valeant announced Monday that they had dismissed the entire sales force associated with Flibanserin and would reintroduce the drug later in the year. When Flibanserin first hit the shelves last year, we took a deep dive into its marketing message and the nebulous world of prescription drugs and female desire. On the Media is supported by listeners like you. Support OTM by donating today (https://pledge.wnyc.org/support/otm). Follow our show on Instagram, Twitter and Facebook @onthemedia, and share your thoughts with us by emailing [email protected].
No persons identified in this episode.
No transcription available yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster